GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) has earned an average rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $41.67.
WGS has been the topic of several analyst reports. TD Cowen increased their price target on shares of GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. BTIG Research increased their price target on shares of GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Craig Hallum increased their price target on shares of GeneDx from $43.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. The Goldman Sachs Group raised their target price on shares of GeneDx from $32.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, October 16th. Finally, Wells Fargo & Company started coverage on shares of GeneDx in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $34.00 target price on the stock.
Read Our Latest Stock Analysis on GeneDx
Insider Buying and Selling at GeneDx
Hedge Funds Weigh In On GeneDx
A number of hedge funds have recently bought and sold shares of the company. Raymond James & Associates bought a new position in GeneDx during the third quarter worth $8,090,000. CWM LLC bought a new position in GeneDx during the third quarter worth $89,000. SG Americas Securities LLC bought a new stake in GeneDx in the third quarter valued at $198,000. Point72 Asset Management L.P. increased its stake in GeneDx by 227.4% in the second quarter. Point72 Asset Management L.P. now owns 156,745 shares of the company’s stock valued at $4,097,000 after purchasing an additional 108,864 shares in the last quarter. Finally, Algert Global LLC bought a new stake in GeneDx in the second quarter valued at $356,000. Institutional investors own 61.72% of the company’s stock.
GeneDx Stock Up 7.2 %
Shares of WGS opened at $60.05 on Wednesday. The company has a current ratio of 2.38, a quick ratio of 2.22 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $1.57 billion, a PE ratio of -11.59 and a beta of 2.32. The firm’s 50 day moving average is $40.84 and its 200-day moving average is $29.54. GeneDx has a 12 month low of $1.16 and a 12 month high of $61.96.
GeneDx (NASDAQ:WGS – Get Free Report) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.15. The business had revenue of $70.51 million for the quarter, compared to analyst estimates of $58.90 million. GeneDx had a negative net margin of 48.21% and a negative return on equity of 22.71%. Equities research analysts forecast that GeneDx will post -0.75 EPS for the current year.
GeneDx Company Profile
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Read More
- Five stocks we like better than GeneDx
- Stock Average Calculator
- Is Spotify Stock Poised to Soar? Options Traders Think So
- How to Calculate Return on Investment (ROI)
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.